| Title |
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas
|
|---|---|
| Published in |
Investigational New Drugs, August 2017
|
| DOI | 10.1007/s10637-017-0503-7 |
| Pubmed ID | |
| Authors |
Franciele Cristina Kipper, Andrew Oliveira Silva, André Luis Marc, Gláucia Confortin, Augusto Valadão Junqueira, Eliseu Paglioli Neto, Guido Lenz |
| Abstract |
Glioblastoma (GBM) is a very aggressive tumor that has not had substantial therapeutic improvement since the introduction of temozolomide (TMZ) in combination with radiotherapy. Combining TMZ with other chemotherapeutic agents is a strategy that could be further explored for GBM. To search for molecular predictors of TMZ resistance, the TCGA (The Cancer Genome Atlas) database was utilized to assess the impact of specific genes on TMZ response. Patients whose tumors expressed low levels of FGFR3 and AKT2 responded poorly to TMZ. Combination treatment of vinblastine (VBL) plus mebendazole (MBZ) with TMZ was more effective in reducing cell number in most cultures when compared to TMZ alone, especially in cells with low expression levels of FGFR3 and AKT2. Cell cycle distribution and nuclear morphometric analysis indicated that the triple combination of TMZ, VBL and MBZ (TVM) was able to induce polyploidy and senescence, in addition to increasing the Notch3 RNA level in patient-derived gliomas. Thus, this set of data suggests that the triple combination of TMZ, VBL and MBZ may be a considerable therapeutic alternative for the TMZ-tolerant gliomas that harbor low expression of FGFR3/AKT2. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 6 | 15% |
| Student > Ph. D. Student | 6 | 15% |
| Researcher | 6 | 15% |
| Student > Bachelor | 6 | 15% |
| Lecturer | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 13 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 15% |
| Biochemistry, Genetics and Molecular Biology | 6 | 15% |
| Chemistry | 3 | 7% |
| Neuroscience | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 17 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2017.
All research outputs
#20,444,703
of 22,999,744 outputs
Outputs from Investigational New Drugs
#982
of 1,173 outputs
Outputs of similar age
#275,890
of 315,948 outputs
Outputs of similar age from Investigational New Drugs
#15
of 18 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,173 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.